Paroxysmal Atrial Fibrillation Clinical Trial
Official title:
Cryoballoon Ablation Without Use of Contrast Dye for the Treatment of Paroxysmal Atrial Fibrillation
Pulmonary vein isolation using cryoballoon ablation is well established method for the
treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting
the full vein occlusion. It is assessed by venography, performed by injecting contrast
through the inner lumen of the balloon catheter after the vein is blocked with a balloon.
Achieving full vein occlusion in certain situations can be challenging and may require
multiple attempts, which may expose the patient to increased doses of contrast and
radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary
veins.
Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which
in some cases may require to start cryoapplication before the vein is fully sealed. This
approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately
adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement
of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes
full sealing of the vein, contributes to further lowering the temperature and leads to full
electrical isolation of the vein, which is the aims of ablation.
All the above-mentioned facts indicate that demonstrating full vein occlusion using
angiography before the initiation of cryoenergy application is of limited value. Moreover,
there are a number of parameters related to cryoballoon ablation that indicate acute and long
term vein isolation.
Taking into account the arguments presented above, it seems that it is possible to perform an
effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique
without confirmation by venography that PV is occluded. Along with dissemination of the
method, such attempts are and will be made by some operators. Therefore, a systematic
approach to this issue is important. It should define the conditions that should be met in
order for the procedure in the proposed modification to be implemented effectively and
safely. In addition, a protocol of ablation for this modification is required.
Pulmonary vein isolation using cryoballoon ablation is well established method for the
treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting
the full vein occlusion. It is assessed by venography, performed by injecting contrast
through the inner lumen of the balloon catheter after the vein is blocked with a balloon.
Achieving full vein occlusion in certain situations can be challenging and may require
multiple attempts, which may expose the patient to increased doses of contrast and
radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary
veins.
Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which
in some cases may require to start cryoapplication before the vein is fully sealed. This
approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately
adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement
of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes
full sealing of the vein, contributes to further lowering the temperature and leads to full
electrical isolation of the vein, which is the aims of ablation.
All the above-mentioned facts indicate that demonstrating full vein occlusion using
angiography before the initiation of cryoenergy application is of limited value. Moreover,
there are a number of parameters related to cryoballoon ablation that indicate acute and long
term vein isolation.
Taking into account the arguments presented above, it seems that it is possible to perform an
effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique
without confirmation by venography that PV is occluded. Along with dissemination of the
method, such attempts are and will be made by some operators. Therefore, a systematic
approach to this issue is important. It should define the conditions that should be met in
order for the procedure in the proposed modification to be implemented effectively and
safely. In addition, a protocol of ablation for this modification is required.
Course of ablation. All ablations will be performed using Medtronic Arctic Front Advance
catheter system as well as future generations of Medtronic cryoballoon catheter systems.
Initially the cryoenergy will be delivered without previous venography confirming full vein
occlusion. Then, in case of vein isolation failure after 5 minutes of cryoenergy delivery,
further attempts to isolate the vein will be preceded by venography.
Statistical analysis. The assumed sample size (N = 50 patients/ 200 veins) will allow to
estimate the number and percentage of pulmonary veins that will be isolated without the use
of contrast.
The statistical analysis will use standard descriptive statistics tools: frequency tables for
categorical variables; extreme values, mean value and standard deviation for normal
distributed variables; and extreme values and quartiles for non-normal distributed variables.
Parameters assessed during the procedure:
Concerning a single energy cryoapplication
1. Possibility of registration (occurrence vs. non-occurrence) of pulmonary vein potentials
before the cryoapplication, and after the occlusion of the vein by the balloon.
2. Time to vein isolation
3. Cryoenergy application time / freezing time
4. The minimum temperature obtained during cryoapplication
5. Time to obtain temperature - 30 ° C and - 40 ° C
6. Temperature after 30, 60 and 90 seconds from the beginning of cryoenergy application
7. Cryoballoon heating time from -30 C to +15 C Concerning the isolation of a single vein
8. Total time to complete isolation of a vein
9. The number of cryoenergy applications
10. Total time of cryoenergy application per vein
Concerning the entire procedure:
11. Total cryoenergy application time per procedure / patient
12. The total amount of contrast
13. Radiation dose
14. Time of radiation
15. Left atrial dwelling time
16. Duration of the procedure (from puncture of the vein to sheaths removal)
Termination of cryoenergy delivery:
1. If temperature does not reach - 30 ° C after 60 seconds of cryoenergy application
(inefficient application).
2. If vein isolation does not occur after 90 seconds of cryoenergy application (inefficient
application).
3. If temperature after 30 seconds of cryoapplication falls lower than - 50° C (unsafe
application).
4. When temperature reaches - 55° C (unsafe application).
5. If phrenic nerve injury occurs or if symptoms suggesting its imminent occurrence are
noticed (unsafe application).
6. If the operator considers that the application is ineffective or performed too distally
(inefficient or unsafe application).
Effective cryoenergy applications will be terminated 120 seconds after vein isolation.
Veins with no recordable pulmonary vein potentials - The above-mentioned veins will be
isolated - 1 application 240 seconds. Applications will be considered effective if the
minimum temperature achieved will be less than 35C and the stimulation performed from the
vein after application will be ineffective.
Supplemental cryoapplications. Supplemental cryoenergy applications will not be delivered
after successful isolation of the vein
Vein isolation assessment. Pulmonary vein isolation will be assessed by demonstrating
entrance and exit block
Phrenic nerve function monitoring. In order to prevent PN injury/ palsy the balloon will be
inflated outside PV ostia and maintained as antrally as possible during vein isolation. For
phrenic nerve function monitoring pacing of the nerve during right pulmonary vein isolation
will be performed. Additionally, intermittent fluoroscopy during pacing will be used for
monitoring diaphragmatic motion. The ablation will be stopped at the first sign of imminent
phrenic nerve injury.
Complications assessed. Transient phrenic nerve injury or palsy (resolving until discharge
after index procedure) is considered a minor complication. Death, stroke, tamponade,
arteriovenous fistula or pseudoaneurysm, persistent (resolving during follow up) or permanent
(if not resolved at end of follow up, but >12 months) phrenic nerve palsy, bleeding with a
decrease in haemoglobin of at least 2 g / dl or any other state requiring prolongation of
hospitalization are considered major complications.
The duration of the project and follow-up. The study is expected to last two years.
Approximately 50 patients will be enrolled, with one year follow-up. All patients will have
follow-up visits in an out-patient clinic at least 3 and 12 months post PVI. Additionally at
6 weeks, 6 and 9 months post ablation telephone follow-up will be conducted by the study
coordinator using standardized questionnaire.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05970120 -
A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter
|
N/A | |
Recruiting |
NCT06014996 -
Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation.
|
N/A | |
Completed |
NCT03624881 -
Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
|
Phase 4 | |
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Recruiting |
NCT05905835 -
Treatment of PAF With the Synaptic System
|
N/A | |
Active, not recruiting |
NCT05534581 -
SINGLE SHOT CHAMPION
|
Phase 4 | |
Active, not recruiting |
NCT05618340 -
PFA for Paroxysmal Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT05024630 -
Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension
|
N/A | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01913522 -
Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration
|
N/A | |
Terminated |
NCT01925885 -
Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)
|
N/A | |
Withdrawn |
NCT01917981 -
Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation
|
Phase 3 | |
Completed |
NCT01842529 -
Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery
|
Phase 2 | |
Completed |
NCT01693107 -
Atrial Fibrillation Force Contact Ablation Study
|
||
Completed |
NCT00971204 -
Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT05043883 -
Automated Assessment of PVI Using a Novel EP Recording System
|
N/A | |
Recruiting |
NCT05172765 -
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
|
N/A | |
Recruiting |
NCT04529785 -
Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation
|
N/A | |
Completed |
NCT04022954 -
HD Mapping of Atrial Fibrillation in Asia Pacific
|
||
Completed |
NCT00964392 -
NAVISTAR® THERMOCOOL® Catheter Post Approval Registry
|
Phase 4 |